Regencell Bioscience Holdings Limited (RGC)

RGC Cash Flow Statement

Financials in millions USD. Fiscal year is July - June.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Net Income	-3.58	-4.36	-6.06	-7.59	-1.35
Depreciation & Amortization	0.39	0.75	0.77	0.6	0.03
Stock-Based Compensation	0.24	0.45	0.92	2.76	-
Other Adjustments	-0.19	-0.25	-0.08	-0.01	-
Changes in Accrued Expenses	0.22	-0.03	0.01	-0.42	0.48
Changes in Other Operating Activities	-0.2	-0.55	-0.52	-0.6	0.07
Operating Cash Flow	-3.11	-4	-4.96	-5.27	-0.77
Capital Expenditures	-0.15	-0.01	-0.03	-0.78	-
Sale of Property, Plant & Equipment	-	-	0	-	-
Purchases of Investments	-32.48	-5	-10	-10	-
Proceeds from Sale of Investments	35.32	10.25	10.09	-	-
Investing Cash Flow	2.69	5.24	0.06	-10.78	-
Long-Term Debt Repaid	-	-	-	-0.43	0.61
Net Long-Term Debt Issued (Repaid)	-	-	-	-0.43	0.61
Issuance of Common Stock	-	-	-	22.67	-
Net Common Stock Issued (Repurchased)	-	-	-	22.67	-
Other Financing Activities	-	0.1	0.13	0.16	-0.17
Financing Cash Flow	-	0.1	0.13	22.41	0.44
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-0.11	0.05	-0.08	-	-
Net Cash Flow	-0.54	1.4	-4.85	6.36	-0.33
Free Cash Flow	-3.27	-4.01	-4.99	-6.05	-0.77
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.01	-0.00
Levered Free Cash Flow	-3.33	-4.15	-5.64	-9.08	-0.16
Unlevered Free Cash Flow	-3.51	-4.58	-6.04	-8.82	-0.8

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q